These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 35537758)

  • 21. Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy.
    Milazzo L; Pezzati L; Oreni L; Kullmann C; Lai A; Gabrieli A; Bestetti G; Beschi C; Conti F; Ottomano C; Gervasoni C; Meroni L; Galli M; Antinori S; Ridolfo AL
    Hum Vaccin Immunother; 2021 Dec; 17(12):4747-4754. PubMed ID: 35086438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine.
    Messali S; Bertelli A; Campisi G; Zani A; Ciccozzi M; Caruso A; Caccuri F
    J Med Virol; 2021 Dec; 93(12):6468-6470. PubMed ID: 34329486
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients.
    Pitzalis M; Idda ML; Lodde V; Loizedda A; Lobina M; Zoledziewska M; Virdis F; Delogu G; Pirinu F; Marini MG; Mingoia M; Frau J; Lorefice L; Fronza M; Carmagnini D; Carta E; Orrù V; Uzzau S; Solla P; Loi F; Devoto M; Steri M; Fiorillo E; Floris M; Zarbo IR; Cocco E; Cucca F
    Front Immunol; 2021; 12():781843. PubMed ID: 34956211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia: A Serologic and Cellular Study.
    Molica S; Giannarelli D; Lentini M; Zappala D; Mannella A; Loiacono D; Gianfelici V; Panduri G; Gariani I; Minchella P; Talarico F; Levato L
    Chemotherapy; 2022; 67(2):91-95. PubMed ID: 34872098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study' by Shasha et al.
    Scorza FA; Finsterer J
    Clin Microbiol Infect; 2022 Mar; 28(3):452-453. PubMed ID: 34839005
    [No Abstract]   [Full Text] [Related]  

  • 26. Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination.
    Pedersen RM; Bang LL; Madsen LW; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
    Emerg Infect Dis; 2022 Jun; 28(6):1274-1275. PubMed ID: 35356875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine is not influenced by AB0 blood group in subjects with transfusion-dependent thalassemia.
    Sgherza N; Zucano S; Vitucci A; Palma A; Campanale D; Larocca AMV; Visceglie D; Acquafredda A; Musto P
    Acta Biomed; 2022 May; 93(2):e2022134. PubMed ID: 35546002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273.
    Steensels D; Pierlet N; Penders J; Mesotten D; Heylen L
    JAMA; 2021 Oct; 326(15):1533-1535. PubMed ID: 34459863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maternal COVID-19 Vaccine Safe for Infants.
    Slomski A
    JAMA; 2022 Apr; 327(13):1218. PubMed ID: 35380595
    [No Abstract]   [Full Text] [Related]  

  • 31. Short-term Adverse Events After the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine in Adults 60 Years or Older.
    Auster O; Finkel U; Dagan N; Barda N; Laufer A; Balicer RD; Ben-Shachar S
    JAMA Netw Open; 2022 Apr; 5(4):e227657. PubMed ID: 35435973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
    Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
    JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Similar humoral immune responses in peritoneal dialysis and haemodialysis patients after two doses of the SARS-CoV-2 vaccine BNT162b2.
    Patecki M; Merscher S; Dumann H; Bernhardt W; Dopfer-Jablonka A; Cossmann A; Stankov MV; Einecke G; Haller H; Schlieper G; Behrens GM
    Perit Dial Int; 2022 Jan; 42(1):100-101. PubMed ID: 34753339
    [No Abstract]   [Full Text] [Related]  

  • 35. The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine : A Retrospective Cohort Study.
    Gazit S; Shlezinger R; Perez G; Lotan R; Peretz A; Ben-Tov A; Herzel E; Alapi H; Cohen D; Muhsen K; Chodick G; Patalon T
    Ann Intern Med; 2022 May; 175(5):674-681. PubMed ID: 35157493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.
    Nam SY; Jeon SW; Lee HS; Lim HJ; Lee DW; Yoo SS
    JAMA Netw Open; 2022 May; 5(5):e2212996. PubMed ID: 35587345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BNT162B2 mRNA COVID-19 Vaccine in Heart and Lung Transplanted Young Adults: Is an Alternative SARS-CoV-2 Immune Response Surveillance Needed?
    Cotugno N; Pighi C; Morrocchi E; Ruggiero A; Amodio D; Medri C; Colagrossi L; Russo C; Di Cesare S; Santilli V; Manno EC; Zangari P; Giancotta C; Bernardi S; Nicolosi L; Ciofi Degli Atti M; Raponi M; Zaffina S; Alfieri S; Kirk R; Perno CF; Rossi P; Amodeo A; Palma P
    Transplantation; 2022 Feb; 106(2):e158-e160. PubMed ID: 34954734
    [No Abstract]   [Full Text] [Related]  

  • 38. Effectiveness of BNT162b2 vaccine against the B.1.1.7 variant of SARS-CoV-2 among healthcare workers in Brescia, Italy.
    Sansone E; Tiraboschi M; Sala E; Albini E; Lombardo M; Castelli F; De Palma G
    J Infect; 2021 Jul; 83(1):e17-e18. PubMed ID: 33965428
    [No Abstract]   [Full Text] [Related]  

  • 39. Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2.
    Kayukawa S; Nanya K; Morita M; Ina K; Ota Y; Hasegawa S
    Microbiol Spectr; 2021 Dec; 9(3):e0103621. PubMed ID: 34756062
    [No Abstract]   [Full Text] [Related]  

  • 40. Reporting of health equity considerations in vaccine trials for COVID-19: comment on Kou et al.
    Daungsupawong H; Wiwanitkit V
    J Clin Epidemiol; 2024 Jul; 171():111329. PubMed ID: 38521365
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.